Tilray (TLRY) Competitors $1.35 -0.03 (-2.17%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TLRY vs. CRON, USNA, MNMD, CDXC, CGC, BTMD, ACB, FOMX, MDWD, and FTLFShould you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), ChromaDex (CDXC), Canopy Growth (CGC), biote (BTMD), Aurora Cannabis (ACB), Menlo Therapeutics (FOMX), MediWound (MDWD), and FitLife Brands (FTLF). Tilray vs. Cronos Group USANA Health Sciences Mind Medicine (MindMed) ChromaDex Canopy Growth biote Aurora Cannabis Menlo Therapeutics MediWound FitLife Brands Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do analysts rate TLRY or CRON? Tilray currently has a consensus target price of $2.63, indicating a potential upside of 94.44%. Cronos Group has a consensus target price of $3.00, indicating a potential upside of 49.25%. Given Tilray's stronger consensus rating and higher possible upside, research analysts plainly believe Tilray is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the MarketBeat Community prefer TLRY or CRON? Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.21% of users gave Tilray an outperform vote. CompanyUnderperformOutperformTilrayOutperform Votes44759.21% Underperform Votes30840.79% Cronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Which has more volatility & risk, TLRY or CRON? Tilray has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Which has stronger valuation & earnings, TLRY or CRON? Cronos Group has lower revenue, but higher earnings than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTilray$788.94M1.55-$244.98M-$0.27-5.00Cronos Group$87.24M8.81-$73.96M-$0.13-15.46 Do institutionals and insiders hold more shares of TLRY or CRON? 9.4% of Tilray shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 0.9% of Tilray shares are held by company insiders. Comparatively, 6.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor TLRY or CRON? In the previous week, Cronos Group had 1 more articles in the media than Tilray. MarketBeat recorded 17 mentions for Cronos Group and 16 mentions for Tilray. Tilray's average media sentiment score of 0.32 beat Cronos Group's score of 0.29 indicating that Tilray is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TLRY or CRON more profitable? Tilray has a net margin of -26.79% compared to Cronos Group's net margin of -42.65%. Tilray's return on equity of -2.00% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Tilray-26.79% -2.00% -1.60% Cronos Group -42.65%-2.56%-2.47% SummaryTilray beats Cronos Group on 11 of the 18 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get Tilray News Delivered to You Automatically Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLRY vs. The Competition Export to ExcelMetricTilrayMedicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$1.22B$1.26B$14.91B$8.66BDividend YieldN/AN/A2.67%4.06%P/E Ratio-5.0045.4223.6817.45Price / Sales1.557.383.5269.07Price / CashN/A12.9221.1036.36Price / Book0.331.945.955.87Net Income-$244.98M-$52.95M$582.17M$225.66M7 Day Performance-9.40%-2.37%-0.67%-1.34%1 Month Performance-14.01%-2.50%-2.71%1.15%1 Year Performance-26.23%7.07%10.46%24.02% Tilray Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLRYTilray2.0085 of 5 stars$1.35-2.2%$2.63+94.4%-22.9%$1.22B$788.94M-5.002,650Options VolumeCRONCronos Group1.8769 of 5 stars$2.17-4.0%N/A+7.5%$829.59M$87.24M-16.69356Short Interest ↓Analyst RevisionNews CoverageUSNAUSANA Health Sciences2.8527 of 5 stars$40.91+1.0%N/A-11.8%$779.75M$921.01M14.461,800MNMDMind Medicine (MindMed)2.7154 of 5 stars$8.40+2.6%N/A+215.4%$605.62MN/A-3.7157Options VolumeNews CoverageGap UpCDXCChromaDex4.3851 of 5 stars$7.01-3.3%N/A+367.1%$535.42M$83.57M701.70106Short Interest ↓Gap DownHigh Trading VolumeCGCCanopy Growth1.6253 of 5 stars$3.94flatN/A-29.7%$369.81M$220.27M-0.801,029Short Interest ↓Analyst RevisionBTMDbiote3.4008 of 5 stars$6.72+21.7%N/A+11.1%$364.36M$185.36M25.85194Short Interest ↓Analyst RevisionNews CoverageHigh Trading VolumeACBAurora Cannabis0.6614 of 5 stars$4.54-4.0%N/A-9.7%$248.99M$296.99M-5.971,073Short Interest ↑News CoverageFOMXMenlo TherapeuticsN/A$2.99flatN/AN/A$184.12M$3.60M-2.3080MDWDMediWound2.0214 of 5 stars$16.60-1.8%N/A+93.2%$179.11M$18.69M-7.6980Upcoming EarningsPositive NewsFTLFFitLife Brands4.3562 of 5 stars$34.88+3.3%N/A+52.6%$160.45M$52.70M21.6620Short Interest ↓Analyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies CRON Competitors USNA Competitors MNMD Competitors CDXC Competitors CGC Competitors BTMD Competitors ACB Competitors FOMX Competitors MDWD Competitors FTLF Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLRY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tilray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tilray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.